The FDA advised providers to record the specific GBCA and the dosage given to each patient.
Do not exceed recommended dose and prior to re-administration, allow sufficient time for elimination from body, respecting half life.
For patients who are receiving hemodialysis, consider promptly initiating hemodialysis following GBCA administration.
Present patients with a list of symptoms.
Report adverse events with GBCAs to Fed's MedWatch program.
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.